Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
"OFFICIAL PARTNER RESMI FIFA WORLD CUP 2018 RUSSIA!
Ayo segera bergabung bersama kami dan Dukung Negara Jagoan kamu hanya di BOLAVITA
Info Lebih Lanjut Bisa Hub CS kami :
wechat : bolavita
whatup : 6281377055002
BBM: BOLAVITA(NEW)"
"Dapatkan berbagai bonus dari POKERVITA
♣♣ Bonus Hariaan Hingga 3juta
♣♣ Bonus Bulanan Hadiah Spesial untuk member yang bermain selama 1 bulan penuh
♣♣ Bonus cashback 0.5 % (Mingguan)
♣♣ Bonus Referensi 20% (Seumur hidup)
Contact Us Person :
? WA: 082312256064
? BBM : D88B0154"
